ITIH4 and AIDS: While a vaccine against HIV/AIDS has remained elusive since the pandemic first appeared, the recent findings from the phase III Thailand clinical trial with the combination of a canary poxvirus vector (ALVAC) and purified protein gp120 (RV144) giving 31.2% protection against HIV infection [1], while it was not sustain, it open the possibility of improving HIV/AIDS efficacy through modification of some of the vaccine components similar as those used in the Thai trial.